SINTX TECHNOLOGIES ANNOUNCES PUBLICATION OF STUDY TO REDUCE THE SPREAD AND TRANSFER OF CORONAVIRUS
June 24 2020 - 9:00AM
SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”),
an original equipment manufacturer (OEM) ceramics company focused
on silicon nitride and its applications, today announced positive
testing results demonstrating the anti-viral properties of its
silicon nitride which may be useful in the reduction of the spread
of COVID-19. The study results demonstrated that SINTX’s unique
grade of silicon nitride inactivates the SARS-CoV-2 virus within a
minute after exposure, and has the potential to decrease the risk
of viral disease spread on surfaces.
Studies have shown that coronavirus spreads
between humans when an infected person coughs or sneezes. Also, the
virus can remain active on a variety of commonly touched surfaces
for hours to days. SINTX believes that by incorporating its unique
composition of silicon nitride into products such as face masks,
and personal protective equipment, it is possible to manufacture
surfaces that inactivate viral particles, thereby limiting the
spread of the disease. SINTX envisions incorporating its silicon
nitride into high-contact surfaces such as medical equipment,
screens, countertops, and doorknobs in locations where viral
persistence is a concern, such as homes, casinos, and cruise
ships.
“The study builds upon years of research toward
understanding the basic biochemistry of silicon nitride,” said Dr.
Sonny Bal, President, and CEO of SINTX. “The antiviral attributes
of silicon nitride are consistent with the known antibacterial
behavior of silicon nitride. The results with coronavirus
inactivation are likewise consistent with an earlier study that
showed similar inactivation of other viruses, including Influenza A
and Enterovirus, both of which cause human disease.”
“The study and testing results show promise
toward developing a new category of face masks for healthcare
professionals and general consumers,” said Bruce Lorange, Founder,
and CEO, O2TODAY. “Face masks used by healthcare workers today can
capture virus particles, but the virus can remain viable in the
mask, even as long 7 days after use. Inclusion of silicon nitride
technology into the mask may enhance personal safety while reducing
the risk of disease spread.”
“This antiviral discovery opens many new
opportunities for SINTX. In composites, coatings, and mixtures,
silicon nitride has maintained its antibacterial and osteogenic
properties, even at small fractions. We believe that incorporating
our material into a variety of commonly-touched surfaces will
discourage viral spread, and contribute to global health by
reducing the risk of disease,” Dr. Bal added.
The present study was done independently, with
SINTX supplying its silicon nitride for the testing. The complete
data and study can be downloaded at bioRxiv. Additional tests are
underway at several U.S. research centers to further understand the
isolation and optimization of the antiviral properties of silicon
nitride; those results will be shared as they become available.
About SINTX Technologies,
Inc.
SINTX Technologies is an OEM ceramics company
that develops and commercializes silicon nitride for medical and
non-medical applications. The core strength of SINTX Technologies
is the manufacturing, research, and development of silicon nitride
ceramics for external partners. The Company manufactures silicon
nitride material and components in its FDA registered and ISO 13485
certified facility. For more information on SINTX Technologies or
its silicon nitride material platform, please visit
www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended (PSLRA) that are subject to several
risks and uncertainties. Risks and uncertainties that may cause
such differences to include, among other things, that SINTX has not
developed any PPE products which incorporate the use of silicon
nitride, incorporation of silicon nitride into PPE may not be safe
or effective; the uncertainties inherent in research and
development, including the cost and time required to advance our
products to regulatory submission; market acceptance of our
products once cleared and commercialized; our ability to raise
additional funding and other competitive developments. Readers are
cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date on which they are made
and reflect management’s current estimates, projections,
expectations, and beliefs. There can be no assurance that any of
the anticipated results will occur on a timely basis or at all due
to certain risks and uncertainties, a discussion of which can be
found in SINTX’s Risk Factors disclosure in its Annual Report on
Form 10-K, filed with the Securities and Exchange Commission (SEC)
on March 26, 2020, and in SINTX’s other filings with the SEC. SINTX
disclaims any obligation to update any forward-looking statements.
SINTX undertakes no obligation to publicly revise or update the
forward-looking statements to reflect events or circumstances that
arise after the date of this report.
Business Inquiries for
SINTX:SINTX Technologies801.839.3502IR@sintx.com
Media Inquiries for SINTX:
Amanda Barry Account Manager, Content and PR The Summit Group +1
509.554.8409 abarry@summitslc.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Aug 2024 to Sep 2024
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Sep 2023 to Sep 2024